Results 201 to 210 of about 354,007 (274)
Some of the next articles are maybe not open access.
American Journal of Rhinology and Allergy, 2019
Background Histamine and leukotriene are released after being triggered by allergen exposure. The combination of leukotriene receptor antagonist (LTRA) and H1-antihistamine (AH) is utilized to control the allergic rhinitis (AR) symptoms after the failure
Kornkiat Snidvongs +2 more
exaly +2 more sources
Background Histamine and leukotriene are released after being triggered by allergen exposure. The combination of leukotriene receptor antagonist (LTRA) and H1-antihistamine (AH) is utilized to control the allergic rhinitis (AR) symptoms after the failure
Kornkiat Snidvongs +2 more
exaly +2 more sources
Pharmacological Research, 1999
The demonstration that leukotrienes, mainly cysteinyl leukotrienes, have biological properties relevant to the pathogenesis of asthma has stimulated the development of many therapeutic compounds to block these deleterious effects. Two main classes of leukotriene modulators have been developed: CysLT1 receptor antagonists and leukotriene synthesis ...
P Devillier
exaly +3 more sources
The demonstration that leukotrienes, mainly cysteinyl leukotrienes, have biological properties relevant to the pathogenesis of asthma has stimulated the development of many therapeutic compounds to block these deleterious effects. Two main classes of leukotriene modulators have been developed: CysLT1 receptor antagonists and leukotriene synthesis ...
P Devillier
exaly +3 more sources
Leukotriene receptor antagonists in chronic urticaria†
Allergy: European Journal of Allergy and Clinical Immunology, 2001. SOME patients with chronic idiopathic urticaria (CIU) do not respond to antihistamines and require long-term steroid administration or even cyclosporin to control their disease. Recently, several studies reported good results with antileukotriene drugs in CIU (1–4); however, a prospective investigation aiming to detect which patients are more likely ...
Riccardo Asero, M Lorini
exaly +3 more sources
Pediatric Pulmonology, 2020
To determine the response of airway mechanics and the changes in asthma symptoms to stepping down of leukotriene receptor antagonist (LTRA) therapy.
J. Kim +9 more
semanticscholar +1 more source
To determine the response of airway mechanics and the changes in asthma symptoms to stepping down of leukotriene receptor antagonist (LTRA) therapy.
J. Kim +9 more
semanticscholar +1 more source
Leukotriene receptor antagonists - an update
Drug and Therapeutics Bulletin, 2005Montelukast (Singulair - MSD) and zafirlukast (Accolate - AstraZeneca) are oral leukotriene receptor antagonists, licensed for the treatment of patients with asthma. In 1998, soon after their launch, we concluded that there was insufficient evidence to clearly define their place in treatment.1 Here, we reconsider their role in adults and children with ...
openaire +2 more sources
Pharmacology of Leukotriene Receptor Antagonists
American Journal of Respiratory and Critical Care Medicine, 1998Abstract Preclinical pharmacological studies have demonstrated that cysLT1 receptor antagonists, such as zafirlukast, montelukast, and pobilukast, are potent and selective antagonists of cysteinyl leukotriene (cysLT) activity. In vitro, these agents compete with [3H]LTD4 for binding to cysLT1 receptors present on guinea pig and human ...
openaire +2 more sources
Leukotriene receptor antagonists for exacerbations of asthma
Paediatric Respiratory Reviews, 2012Emergency department visits and hospital admissions for acute asthma represent a considerable burden on health services worldwide. Many patients presenting with acute asthma do not respond fully to standard therapy of beta2agonists, corticosteroids and oxygen so additional therapies are required.
Emma, Welsh +3 more
openaire +2 more sources